Digital Look

Welcome to Digital Look++,
you are not logged in

Oxford Nanopore Technologies (ONT)

Pharma and Biotech

102.70p

	£ (Millions)	£ (Millions)
Income Statement	30-Jun-23	30-Jun-22
Continuing Operations
Revenue	86.00	122.35
Operating Profit/(Loss)	(74.78)	(22.96)
Profit Before Tax	(66.56)	(27.63)
Profit After Tax	(70.10)	(30.17)
Discontinued Operations
Profit After Tax	n/a	n/a
PROFIT FOR THE PERIOD	(70.10)	(30.17)

Continuing EPS
Earnings per Share - Basic	(8.00p)	(4.00p)
Earnings per Share - Diluted	(8.00p)	(4.00p)
Earnings per Share - Adjusted	(8.00p)	(4.00p)
Continuing and Discontinued EPS
Earnings per Share - Basic	(8.00p)	(4.00p)
Earnings per Share - Diluted	(8.00p)	(4.00p)
Earnings per Share - Adjusted	(8.00p)	(4.00p)
Dividend per Share	n/a	n/a

	£ (Millions)	£ (Millions)
Balance Sheet	30-Jun-23	30-Jun-22
Total Non-Current Assets	213.85	89.02
Net Current Assets	_cn/a	_cn/a
Total Assets	758.82	842.29
Total Liabilities	117.61	116.21
Net Assets	641.21	726.08

Shareholders Funds	641.21	726.08
Minority Interests/Other Equity	n/a	n/a
Total Equity	641.21	726.08

* GAAP

a. Includes discontinued activities

b. Including assets due in more than one year

c. Not disclosed under IFRS

d. Total fixed assets

e. Includes borrowings

f. Included in cash flow from operating activities under IFRS

g. Included in net cash from investing activities under IFRS

h. Pre-tax

i. Capital expenditure

j. Based on operating cash flow before tax

k. Issue of ordinary shares

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: Forecast figures based on normalised accounts.